16 results
Primary objective: to define the maximal tolerated dose (MTD) of Olaparib in combination with high dose radiotherapy with and without daily dose cisplatin in locally advanced non-small cell lung carcinoma.
To determine if FDG PET/CT is performant enough with respect to detecting residual lymph node involvement after chemoradiation in order to omit planned neck dissections in patients with locally advanced potentially operable, N2 and N3 head and neck…
This Phase II trial aims to:1 Test the predictive value of Zr89 Cetuximab uptake in vivo for treatment specific outcome 2 Explore the impact of dose redistribution on loco-regional control and disease free survival.If individualized treatment…
The primary objective of this study is to evaluate overall survival (OS) in the intent-to-treat (ITT) subject population defined by this protocol.Key secondary objectives are to evaluate OS in the epidermal growth factor receptor (EGFR) wild type…
The primary objective of this study is to determine the response rate of electrochemotherapy in head and neck cancer. Secondary objectives are to monitor local and systemic side effects and adverse events and to determine quality of life before and…
The aim of this research is to gain a more detailed insight into the illness perceptions of patients with lung cancer. With this insight it is our aim to improve biopsychosocial care for these patients. Research question: What are the illness…
The primary objective of this study is to compare the Overall Survival (OS) of first-linemaintenance therapy with erlotinib versus erlotinib administered at the time of diseaseprogression in patients with histologically documented, advanced or…
To compare the feasibility of mutation analysis in samples obtained with EUS-FNA and EUS-TCB in patients with mediastinal lymph node metastasis in NSCLC. To compare EUS-TCB with EUS-FNA in diagnosing benign and malignant mediastinal disease.
Primary Objective: The primary objective is to investigate whether EUS-TCB had an added value on EUS-FNA alone. Secondary Objective(s): The secondary objective is to study whether EUS-TCB does not have a higher complication rate than EUS-FNA alone.
Primary Objective: To compare Overall Survival (OS) of subjects with Stage IV/recurrent NSCLC of squamous histology who have been randomized to ipilimumab in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel and…
Run-in phase I: To confirm the safety and tolerability of BIBF 1120 up to a dose level of 200 mg b.i.d added to a standard dose of cisplatin/gemcitabine in first line NSCLC patients with squamous cell histology. Pharmacokinetics of BIBF 1120 and…
To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy, pemetrexed/cisplatin or pemetrexed/carboplatin (Arm B), in prolonging PFS in patients with advanced non-squamous NSCLC whose tumors harbor a translocation or inversion…
To compare the therapeutic benefit of maintenance pazopanib versus placebo after first line treatment of NSCLC.
To assess sorafenib pharmacokinetics and biodistribution, K-Ras mutational status, tumor uptake and tumor response in NSCLC patients.
Primary objective: the assessment of the maximal mean lung dose that is accepted to safely treat large peripheral tumors or 2 lung metastases simultaneously using SBRT. Secondary objectives:- evaluation of local control - evaluation of regional…
This is an exploratory study to assess the presence, specificity, type and strength of systemic and local specific cellular immune responses in patients with lung adenocarcinoma at different time-points during routine diagnostic work-up and…